P & T : a Peer-reviewed Journal for Formulary Management

No abstract text is available yet for this article.

Study Objective: The primary aim was to compare postoperative pain scores in patients undergoing laparoscopic cholecystectomy and receiving intravenous (IV) or oral (PO) acetaminophen (APAP) as part of a multimodal analgesic regimen to examine whether PO APAP is non-inferior to IV APAP. Design: Retrospective analysis. Setting: Ambulatory surgical center (ASC) in an academic setting. Patients: 579 patients (18-70 years old), American Society of Anesthesiologists physical status I-III, undergoing laparoscopic cholecystectomy...

Purpose: To assess how patient adherence to atypical antipsychotic medications is associated with adherence to concurrently used medications that treat other serious mental illnesses (SMIs), type-2 diabetes, or hypertension. Methods: Among patients who had been diagnosed with an SMI (i.e., bipolar disorder, major depressive disorder, or schizophrenia) in the previous year, we used health-insurance claims data to measure adherence based on medication fills. Patients diagnosed with an SMI were required to have 1) a prescription for an atypical oral antipsychotic, and 2) another SMI therapy or oral anti-diabetic or antihypertensive agent in the same year...

Since the introduction of the 2009 HITECH Act, how has system-wide data sharing fared among hospitals and physician offices? Not that well, according to the CMS. But will the new proposed rules improve things for providers, system developers, and patients?

Intranasal esketamine for treatment-resistant depression.

Sunosi (solriamfetol) tablets for excessive daytime sleepiness with narcolepsy or obstructive sleep apnea; Zulresso (brexanolone) injection for postpartum depression in adults; Mayzent (siponimod) tablets for adults with relapsing forms of MS.

Approvals, new indications and formulations, and safety issues.

Several drug-price "remedy" bills are floating around Congress, with most being described as a "first step." So why is no one referring to that step as significant?

Implementing IT in medication-use systems reduces adverse drug events by decreasing human error. But over-reliance on technology can lead to automation bias and complacency.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

Increased cannabis use has brought about a sea change in policy and attitudes toward regulation, and a multitude of rules that vary widely between states. The disparity has stymied any effective response to the problems surrounding access to cannabis products for those in need. Health care providers and practitioners, as well as P&T committees, must carefully undertake decisions on rational drug use, whether or not their patients are using cannabis while under their care.

This in-depth article on the sixth leading cause of death in the U.S. reports on the optimism of cutting-edge leaders in Alzheimer's disease research. The author examines key considerations such as the status of biomarker tests, and the search for new biomarkers; securing an accurate definition of the disease; risk factors; clinical trials and non-pharmacological studies.

We report on two sessions on atrial fibrillation, two on heart failure, two on hypertension, and one each on endocarditis and ST-elevation myocardial infarction.

Virtual reality (VR) has been widely studied and applied in numerous medical applications.1 In pharmacy, VR can potentially be applied as follows: adjunctively or as a replacement for pharmacotherapy; in drug design and discovery; in pharmacist education; and in patient counseling and behavior modification.1-6 Research applying VR in pharmacy is currently limited; however, interest in these applications is increasing. The majority of studies conducted during the past decade have found VR to be safe and effective, and to promote a high degree of user satisfaction...

What lies behind the growth of rising hospital prices? Many factors-including the impact of hospital mergers and the industry's complicated relationship with Congress.

Cannabidiol oral solution for seizures associated with Lennox-Gastaut and Dravet syndromes.

Cablivi (caplacizumab-yhdp) for acquired thrombotic thrombocytopenic purpura; Egaten (triclabendazole) for fascioliasis; and Spravato (esketamine) for treatment-resistant depression.

Approvals, new indications and formulations, and safety issues.